BACKGROUND AND OBJECTIVES: Most studies of chronic kidney disease (CKD) and outcomes focus on mortality and ESRD, with limited data on other adverse outcomes. This study examined the associations among proteinuria, eGFR, and adverse cardiovascular (CV) events. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a population-based longitudinal study with patients identified from province-wide laboratory data from Alberta, Canada, between 2002 and 2007. Selected for this study from a total of 1,526,437 patients were 920,985 (60.3%) patients with at least one urine dipstick measurement and 102,701 patients (6.7%) with at least one albumin-creatinine ratio (ACR) measurement. Time to hospitalization was considered for one of four indications: congestive heart failure (CHF), coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI), peripheral vascular disease (PVD), and stroke/transient ischemic attacks [TIAs] (cerebrovascular accident [CVA]/TIA). RESULTS: After a median follow-up of 35 months, in fully adjusted models and compared with patients with estimated GFR (eGFR) of 45 to 59 ml/min per 1.73 m(2) and no proteinuria, patients with heavy proteinuria by dipstick and eGFR ≥ 60 ml/min per 1.73 m(2) had higher rates of CABG/PCI and CVA/TIA. Similar results were obtained in patients with proteinuria measured by ACR. CONCLUSIONS: Risks of major CV events at a given level of eGFR increased with higher levels of proteinuria. The findings extend current data on risk of mortality and ESRD. Measurement of proteinuria is of incremental prognostic benefit at every level of eGFR. The data support use of proteinuria measurement with eGFR for definition and risk stratification in CKD.
BACKGROUND AND OBJECTIVES: Most studies of chronic kidney disease (CKD) and outcomes focus on mortality and ESRD, with limited data on other adverse outcomes. This study examined the associations among proteinuria, eGFR, and adverse cardiovascular (CV) events. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a population-based longitudinal study with patients identified from province-wide laboratory data from Alberta, Canada, between 2002 and 2007. Selected for this study from a total of 1,526,437 patients were 920,985 (60.3%) patients with at least one urine dipstick measurement and 102,701 patients (6.7%) with at least one albumin-creatinine ratio (ACR) measurement. Time to hospitalization was considered for one of four indications: congestive heart failure (CHF), coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI), peripheral vascular disease (PVD), and stroke/transient ischemic attacks [TIAs] (cerebrovascular accident [CVA]/TIA). RESULTS: After a median follow-up of 35 months, in fully adjusted models and compared with patients with estimated GFR (eGFR) of 45 to 59 ml/min per 1.73 m(2) and no proteinuria, patients with heavy proteinuria by dipstick and eGFR ≥ 60 ml/min per 1.73 m(2) had higher rates of CABG/PCI and CVA/TIA. Similar results were obtained in patients with proteinuria measured by ACR. CONCLUSIONS: Risks of major CV events at a given level of eGFR increased with higher levels of proteinuria. The findings extend current data on risk of mortality and ESRD. Measurement of proteinuria is of incremental prognostic benefit at every level of eGFR. The data support use of proteinuria measurement with eGFR for definition and risk stratification in CKD.
Authors: Ron T Gansevoort; Jacobien C Verhave; Hans L Hillege; Johannes G M Burgerhof; Stephan J L Bakker; Dick de Zeeuw; Paul E de Jong Journal: Kidney Int Suppl Date: 2005-04 Impact factor: 10.545
Authors: Erik M Stuveling; Hans L Hillege; Stephan J L Bakker; Folkert W Asselbergs; Paul E de Jong; Reinold O B Gans; Dick de Zeeuw Journal: Atherosclerosis Date: 2004-01 Impact factor: 5.162
Authors: Eric L Knight; Eric B Rimm; Jennifer K Pai; Kathryn M Rexrode; Carolyn C Cannuscio; JoAnn E Manson; Meir J Stampfer; Gary C Curhan Journal: J Am Soc Nephrol Date: 2004-07 Impact factor: 10.121
Authors: Klaus Klausen; Knut Borch-Johnsen; Bo Feldt-Rasmussen; Gorm Jensen; Peter Clausen; Henrik Scharling; Merete Appleyard; Jan Skov Jensen Journal: Circulation Date: 2004-06-21 Impact factor: 29.690
Authors: Kristian Wachtell; Hans Ibsen; Michael H Olsen; Knut Borch-Johnsen; Lars H Lindholm; Carl Erik Mogensen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristianson; Ole Lederballe-Pedersen; Markku S Nieminen; Peter M Okin; Per Omvik; Suzanne Oparil; Hans Wedel; Steven M Snapinn; Peter Aurup Journal: Ann Intern Med Date: 2003-12-02 Impact factor: 25.391
Authors: Kunihiro Matsushita; Shoshana H Ballew; Josef Coresh; Hisatomi Arima; Johan Ärnlöv; Massimo Cirillo; Natalie Ebert; Jade S Hiramoto; Heejin Kimm; Michael G Shlipak; Frank L J Visseren; Ron T Gansevoort; Csaba P Kovesdy; Varda Shalev; Mark Woodward; Florian Kronenberg Journal: Lancet Diabetes Endocrinol Date: 2017-07-14 Impact factor: 32.069
Authors: Mary Ann Sevick; Mary Korytkowski; Roslyn A Stone; Beth Piraino; Dianxu Ren; Susan Sereika; Yuanyuan Wang; Ann Steenkiste; Lora E Burke Journal: J Acad Nutr Diet Date: 2012-08 Impact factor: 4.910
Authors: Robert G Weaver; Matthew T James; Pietro Ravani; Colin G W Weaver; Edmund J Lamb; Marcello Tonelli; Braden J Manns; Robert R Quinn; Min Jun; Brenda R Hemmelgarn Journal: J Am Soc Nephrol Date: 2020-02-05 Impact factor: 10.121
Authors: Nisha Bansal; Ronit Katz; Cassianne Robinson-Cohen; Michelle C Odden; Lorien Dalrymple; Michael G Shlipak; Mark J Sarnak; David S Siscovick; Leila Zelnick; Bruce M Psaty; Bryan Kestenbaum; Adolfo Correa; Maryam Afkarian; Bessie Young; Ian H de Boer Journal: JAMA Cardiol Date: 2017-03-01 Impact factor: 14.676
Authors: Maryam Afkarian; Ronit Katz; Nisha Bansal; Adolfo Correa; Bryan Kestenbaum; Jonathan Himmelfarb; Ian H de Boer; Bessie Young Journal: Clin J Am Soc Nephrol Date: 2016-06-23 Impact factor: 8.237